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ABSTRACT 
Objective: To compare the effects of vasopressin versus norepinephrine infusion on 
the outcome of kidney injury in septic shock.  
Design and Setting: Post-hoc analysis of the multi-centre double-blind randomized 
controlled trial of vasopressin versus norepinephrine in adult patients who had septic 
shock (VASST).  
Patients and Intervention: 778 patients were randomized to receive a blinded 
infusion of either low-dose vasopressin (0.01-0.03U/min) or norepinephrine infusion 
(5-15µg/min) in addition to open-label vasopressors and were included in the outcome 
analysis. All vasopressors were titrated and weaned to maintain a target blood 
pressure.  
Measurement and results: RIFLE criteria for acute kidney injury were used to 
compare the effects of vasopressin versus norepinephrine. In view of multiple 
simultaneous comparisons a p-value of 0.01 was considered statistically significant. 
Kidney injury was present in 464 patients (59.6%) at study entry. In patients in the 
RIFLE “Risk” category (n=106) vasopressin as compared with norepinephrine was 
associated with a trend to a lower rate of progression to renal “Failure” or “Loss” 
categories (20.8% v 39.6% respectively, p=0.03), and a lower rate of use of renal 
replacement therapy (17.0% v 37.7%, p=0.02). Mortality rates in the “Risk” category 
patients treated with vasopressin compared to norepinephrine were 30.8% v 54.7%, 
p=0.01, but this did not reach significance in a multiple logistic regression analysis 
(OR=0.33, 99%CI 0.10-1.09, p=0.02). The interaction of treatment group and RIFLE 
category was significant in predicting mortality. 
Conclusions: Vasopressin may reduce progression to renal failure and mortality in 
patients at risk of kidney injury who have septic shock.  
Key words: Sepsis; kidney failure; vasopressins; shock, septic 
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INTRODUCTION 
Acute kidney injury is a common complication of sepsis that is associated with high 
mortality [1]. The incidence ranges from 15-50% [2-4], and is associated with a 
mortality rate of 30-75% [2-5]. This variation in reported incidence and outcome is 
partly due to heterogeneous patients and different definitions of kidney injury used in 
these studies. Recently, the acute dialysis quality initiative (ADQI) group 
recommended a consensus definition for kidney injury called the RIFLE criteria [6]. 
Patients are defined as being at “Risk” of kidney injury, having renal “Injury” or 
“Failure”, having “Loss” of renal function or having “End-stage” renal failure based 
on decreased glomerular filtration rate (or increased serum creatinine) and urine 
output. 
 
Despite the high prevalence of acute kidney injury during critical illness in general, 
and severe sepsis specifically, success has been limited in improving the outcome of 
this complication [7]. The mainstays of prevention and treatment include avoidance of 
nephrotoxins and ensuring adequate renal perfusion. In addition to its potent 
vasoconstrictor effects, vasopressin may also have specific beneficial effects on renal 
function secondary to its binding to a family of vasopressin receptors [8]. In several 
small studies of vasodilatory shock, vasopressin increased glomerular filtration rate, 
urine output and creatinine clearance [9-12]. However, to date no large studies have 
assessed the effect of vasopressin, as compared with norepinephrine, on the outcome 
of acute kidney injury. 
 
Therefore, we studied patients who had septic shock recruited to the randomized 
controlled trial of vasopressin versus norepinephrine (VASST: Vasopressin and 
Septic Shock Trial) to compare the effects of vasopressin versus norepinephrine on 
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the outcome of acute kidney injury using the RIFLE criteria. Some of this data has 
been presented in the form of an abstract at the American Thoracic Society 
International Conference, San Francisco, in 2007 [13]. 
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MATERIAL AND METHODS 
Patients 
All patients (n = 779) randomized and infused with study drug from the VASST study 
were included. The study protocol has been previously described [14]. In summary, 
this was a multi-center randomized double-blind controlled trial of vasopressin versus 
norepinephrine in addition to standard vasopressors for the treatment of septic shock.  
Patients were greater than 16 years of age and had septic shock, defined by the 
presence of two or more of the systemic inflammatory response syndrome (SIRS) 
criteria [15], proven or suspected infection, new dysfunction of at least one organ, and 
hypotension despite adequate fluid resuscitation requiring vasopressor support of at 
least 5 µg/min of norepinephrine (or equivalent) for six hours. Important clinical 
exclusion criteria were unstable coronary syndromes, acute mesenteric ischemia, 
severe chronic heart disease (New York Heart Association class III and IV) and 
vasospastic diathesis [14]. Patients were randomized to receive a blinded infusion of 
study drug, either vasopressin (0.01 - 0.03 U/min) or norepinephrine (5 – 15 !g/min). 
The study drug and all other vasopressors were titrated and weaned according to 
protocols. The initial target mean arterial pressure was 65 – 75 mmHg. Other 
treatment decisions (including the need for renal replacement therapy) were at the 
local physician’s discretion. 
 
All patients were classified into one of the RIFLE categories at study baseline (see 
Table 1 for RIFLE classification definitions) based on the rise in serum creatinine 
measured at baseline (i.e., just prior to study drug infusion) compared to the patient’s 
“normal” creatinine. For patients with known chronic renal failure their “normal” 
creatinine was taken as the lowest creatinine measured in the previous 24 hours. For 
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patients without chronic renal failure the “normal” creatinine was taken as the lower 
of: the lowest creatinine measured in the previous 24 hours or the estimated creatinine 
calculated using the MDRD (Modification of Diet in Renal Disease) equation as in 
the original RIFLE description [6]. Patients without end-stage renal failure who were 
receiving renal replacement therapy at study baseline were assigned to the “Failure” 
category as previously described [16]. Patients with known end-stage kidney disease 
at study inclusion were classified as class “E” within RIFLE and were excluded from 
analyses of change in renal function. Details of fluid balance and diuretic therapy 
were available for the first four days of the study only. Data were not available to use 
the urine output criteria for the RIFLE definition.  
 
Statistics 
Outcome measures were 28-day mortality (the primary endpoint of the main trial), 
rate of progression to renal “Failure” / “Loss”, the use of renal replacement therapy 
and serum creatinine over time up to day 28. Survival status at day 90 was also 
recorded. Comparison of outcome between the two treatment groups, vasopressin and 
norepinephrine patients, was performed using the chi-squared test. A multiple logistic 
regression model including age, sex, APACHE II score (measured in the 24 hours 
prior to study inclusion), medical / surgical admission, dose of norepinephrine at 
baseline and treatment group was used to adjust for possible imbalances at baseline 
between the two treatment groups within the patient subgroups in each RIFLE 
category. As the analyses were repeated in each of the five RIFLE classes at baseline 
a Bonferroni correction for multiple testing was applied and a p-value of 0.01 was 
considered statistically significant. 
A linear mixed effects model was used to analyze longitudinal data (i.e., creatinine 
over time). Serum creatinine values were not normally distributed and so the values 
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were log transformed for analysis. This analysis was also repeated adjusting for the 
dose of norepinephrine over time. A differential response to vasopressin compared to 
norepinephrine according to RIFLE category was tested using the interaction terms in 
the regression analyses.  Other continuous variables are presented as mean (± standard 
deviation) or median (interquartile range) and tested using the T-test, ANOVA or 
Mann Whitney U test, as appropriate. 
  9 
 
RESULTS 
 
A total of 779 patients were randomized and infused with study drug, 397 with 
vasopressin, and 382 with norepinephrine. One patient in the vasopressin group was 
lost to follow up at day 28 and therefore only 778 patients were included in the 
outcome analysis. All patients had septic shock and at baseline required a mean 
norepinephrine dose of 20.7 ± 20.2 µg/min to maintain a mean arterial pressure of 
72.7 ± 9.5 mmHg.  The average baseline APACHE II score was 27.1 ± 7.3 and 
patients had 3.4 ± 1.1 organ failures, using the Brussels scoring system [17]. Full 
details of patient characteristics have previously been published [14]. 
 
We compared clinical outcomes between vasopressin-treated patients and 
norepinephrine-treated patients within each RIFLE category (Table 2). Within the 
“Risk” category, there was a trend for less patients to progress to renal “Failure” or 
“Loss” over the 28-day study period in the vasopressin-treated group than the 
norepinephrine group (11 [20.8%] v 21 [39.6%] respectively, p = 0.03). Within the 
“Risk” category, the use of renal replacement therapy at any time during the study 
period was less than half in the vasopressin group compared to the norepinephrine 
group (9 [17.0%] v 20 [37.7%], p = 0.02). There was no significant difference in 
progression of kidney injury between treatment groups in any other RIFLE category. 
 
Serum creatinine decreased more in the “Risk” category of patients who were treated 
with vasopressin as compared with norepinephrine (p = 0.02) despite similar baseline 
creatinine values (Figure 2). This difference remained the same after adjusting for 
dose of norepinephrine (p = 0.02). There was no difference in serum creatinine over 
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time between vasopressin and norepinephrine treated patients in any other RIFLE 
category (Figure 2). There was no significant difference in fluid input, fluid balance 
or diuretic use over the first four days between vasopressin and norepinephrine treated 
patients (data not shown). 
 
We also compared 28-day mortality rates between vasopressin-treated patients and 
norepinephrine-treated patients within each RIFLE category (Table 2). Of those 
patients who were in the “Risk” category, mortality in the vasopressin-treated patients 
compared to norepinephrine-treated patients was 16/52 (30.8%) versus 29/53 (54.7%), 
p = 0.01. There were no significant differences in mortality between treatment groups 
in any other RIFLE category. The interaction of treatment group and RIFLE category 
(“Risk” versus “non-risk”) for 28-day mortality rate was statistically significant (p = 
0.03). However, after adjusting for baseline characteristics (Table 3) using a logistic 
regression model, the odds ratio for mortality in patients randomized to receive 
vasopressin in the Risk category was not statistically significant (OR = 0.33, 99% 
confidence intervals 0.10 – 1.09, p = 0.02). The Kaplan-Meier survival curves 
demonstrate that the variation in mortality rates between vasopressin-treated and 
norepinephrine-treated patients began at about day 2 and then persisted throughout the 
full 90-day follow-up period (p = 0.007, log rank statistic) (Figure 1). 
 
In the “Risk” category, vasopressin was associated with a significant decrease in 
norepinephrine infusion rate from a median of 20 (IQR 8 – 27) !g/min to 9 (IQR 4 – 
23.5) !g/min and the total norepinephrine infusion rate remained lower in the 
vasopressin-treated group throughout the study (Figure 3, Panel A). This vasopressin 
infusion rate maintained mean arterial pressure at values similar to the mean arterial 
pressure in the norepinephrine-treated group (Figure 3, Panel B).  
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Kidney injury (as defined by “Risk” category or worse) was present in 464 (59.6%) of 
patients at baseline (Table 2) and was associated with significantly higher 28-day 
mortality than patients with no kidney injury (44.3% v 27.0%, p < 0.001). A further 
117 patients who had “normal” renal function (non-AKI) at baseline had a 
deterioration in renal function so that in total, 581 (74.6%) patients had kidney injury 
(“Risk” category or worse) at some time during the 28-day study period. 
 
Excluding the 49 patients who had end-stage renal failure prior to inclusion, 532 of 
730 (72.9%) had acute kidney injury during the 28-day study period. Of these 730 
patients, 247 (33.8%) required renal replacement therapy. One hundred and fifty nine 
patients underwent continuous renal replacement therapy, 31 underwent intermittent 
hemodialysis and 57 underwent both types of replacement therapy. Nineteen (4.1%) 
of the 466 survivors without pre-existing end-stage renal failure were still dependent 
on renal replacement therapy at day 28. Of the 49 patients who had end-stage renal 
failure at baseline, 19 were managed with continuous renal replacement therapy, 8 
with intermittent hemodialysis and 22 with both, during the study period. 
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DISCUSSION 
Comparison of vasopressin v norepinephrine 
In this large multi-center study of patients who had septic shock, we found that acute 
kidney injury was very common, found in 73% of patients, and was associated with a 
high mortality rate. In patients who were at risk of kidney injury who had septic shock, 
we found that vasopressin compared to norepinephrine was associated with a trend to 
reduced creatinine over time, reduced progression to renal failure / loss and reduced 
mortality. As a result, fewer patients treated with vasopressin compared to 
norepinephrine required renal replacement therapy.  
 
These results are consistent with previous small studies showing that vasopressin 
compared to norepinephrine increased urine output and creatinine clearance [9-12]. 
The findings in the “Risk” category contrast to those patients who had already 
sustained more severe kidney injury (RIFLE categories “Injury” or “Failure”) at the 
time of study drug infusion; there was no difference in renal function or mortality 
according to vasopressin or norepinephrine allocation. Similarly, there was no 
significant beneficial effect of vasopressin in patients who had no acute kidney injury 
at baseline.  
 
The interaction between treatment group and RIFLE category on mortality was 
significant, suggesting that the response to vasopressin treatment in the “Risk” 
category was significantly different to the response of patients in the other categories 
of RIFLE. These findings raise the possibility that patients classified in the RIFLE 
“Risk” category could be targeted for future therapeutic trials. 
 
Incidence and outcome of acute kidney injury 
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Numerous studies have evaluated the RIFLE criteria in various critically ill 
populations [3, 16, 18-26]. The incidence of acute kidney injury varied between 11% 
and 67% in studies of general ICU patients [16, 18, 20-22]. To our knowledge, the 
current study is the largest study using RIFLE criteria in patients who have septic 
shock.  
 
The 73% incidence of acute kidney injury in this cohort is slightly higher than in 
previous studies. However, this is not surprising, as we studied only severely ill 
patients who had septic shock. Previous studies have shown that the severity of sepsis 
correlates with the incidence of kidney injury [4]. The incidence of acute kidney 
injury we report is substantially higher than the incidence in the most severely ill 
patients described by Rangel-Frausto et al [4], which may reflect between study 
differences due to case mix, or a true increased incidence of acute kidney injury in 
sepsis today compared with the past, as has been suggested by others [20]. The high 
incidence we observed may also reflect greater sensitivity of the RIFLE definitions 
compared to older definitions of renal failure. In RIFLE, a rise in serum creatinine of 
only 50% from baseline is defined as “Risk” [6]. In agreement with previous studies 
examining outcomes using the RIFLE criteria [27, 28], we found that mortality was 
markedly higher among patients who were in the “Risk” category compared to 
patients with non-AKI at enrollment (43% versus 27%, p = 0.002). Our study also 
suggests that patients in the RIFLE “Risk” category were indeed at increased risk of 
renal failure. Half of patients in the “Risk” category had deterioration in renal 
function. Interestingly, it was in the “Risk” subgroup of patients where a beneficial 
effect of vasopressin treatment was observed.  
 
Study limitations 
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There are several limitations of this study. Although we used the consensus RIFLE 
definitions, like many other studies [19, 20] we were not able to asses the urine output 
criteria of the RIFLE definition; thus, the incidence of acute kidney injury using 
RIFLE may actually be higher than the 73% that we observed.  Second, we did not 
examine the mechanisms of potential benefit of vasopressin in this study. Vasopressin 
has complex effects on renal function because of its global hemodynamic effects and 
because of its binding to the vasopressin family of receptors. The renal-specific 
effects of vasopressin include binding to AVPR1a receptors of glomerular efferent 
arterioles which causes glomerular efferent arteriolar vasoconstriction and thus 
increases glomerular filtration [29]. Furthermore vasopressin analogues have been 
shown to increase renal perfusion in decompensated liver cirrhosis [30] and are a 
standard of care in this condition. In contrast, norepinephrine binds to alpha-1 
receptors of renal afferent arterioles and decreases glomerular perfusion pressure and 
filtration [31], although effects may vary between normal healthy states and sepsis 
[32]. Vasopressin-treated patients (Figure 3) had significantly lower norepinephrine 
infusion rates compared to the norepinephrine-treated patients. Mean arterial pressure 
was similar between the two treatment groups (Figure 3). Thus, differences between 
vasopressin and norepinephrine-treated patient outcomes may be due to beneficial 
effects of vasopressin or, alternatively, due to reduction in detrimental effects of 
norepinephrine.   
 
Third, the findings of this post-hoc subgroup analysis should be interpreted cautiously 
[33] since they may represent a chance finding. Although we did correct for multiple 
comparisons some of the RIFLE categories are quite small and there were some 
imbalances in baseline characteristics. Adjusting for these baseline characteristics in a 
multiple logistic regression model resulted in the mortality rates within the “Risk” 
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category no longer reaching statistical significance. However, the RIFLE criteria have 
been previously defined by an independent expert group [6] and have been well 
described in a number of other studies of critically patients [27]. Furthermore, the 
trend to a lower mortality rate in the vasopressin-treated patients at “Risk” of acute 
kidney injury was also accompanied by an improvement in renal function. This may 
provide a biologically plausible explanation for the finding of improved outcome 
associated with vasopressin treatment. This result is also consistent with the primary 
subgroup analysis of the VASST study in which vasopressin treatment was associated 
with decreased mortality in patients who had less severe shock and not in patients 
who had more severe shock [14].  
 
Taken together, these data raise the hypothesis that if there is any benefit of treatment 
using vasopressin in septic shock, it may occur before significant organ failure is 
established. This hypothesis will need further testing. Strategies to improve the 
outcome of established renal failure have so far not provided any convincing benefit 
[34].  
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CONCLUSION 
In a post hoc analysis of this large randomized controlled multicenter study, we found 
that vasopressin was associated with a trend to improved renal function, lower 
mortality and less renal replacement therapy in patients at “Risk” of acute kidney 
injury, but not in those who had already sustained significant renal injury. These 
results will need further testing in another randomized trial before adoption into 
routine clinical practice. 
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Table 1. RIFLE criteria definitions used in this study [6]  
 
 Serum creatinine change criteria  
Risk Increased serum creatinine x1.5  
Injury Increased serum creatinine x2  
Failure  Increased serum creatinine x3 or 
Increased serum creatinine "44!mol/l if 
baseline "350!mol/l  
Loss Persistent acute renal failure = complete 
loss of renal function for > 4 weeks 
End stage  End-Stage Kidney Disease (>3 months) 
 
GFR = Glomerular filtration rate. Serum creatinine 88!mol/l = 1 mg/dl  
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Table 2. Baseline characteristics at time of study drug infusion, 28 day mortality rates and other outcomes according to RIFLE 
categories, and comparing the vasopressin and norepinephrine treatment groups according to RIFLE category.  
 
 Non-AKI Risk 
 Total NE AVP p-value# Total NE AVP p-value# 
Number  315 (40.4) 160 155  106 (13.6) 53 53  
Age 57.8 ± 16.6 59.8 ± 16.7 56.2 ± 16.1 0.06 61.2 ± 16.8 64.3 ± 16.8 58.1 ± 16.4 0.06 
Sex – male 203 (64.4) 101 (63.1) 102 (65.8) 0.70 69 (65.1) 37 (69.8) 32 (60.4) 0.42 
APACHE II 23.7 ± 6.4 24.5 ± 6.0 22.8 ± 6.7 0.007 27.0 ± 6.2 26.9 ± 6.3 27.0 ± 6.2 0.91 
Recent 
Surgery 120 (41.7) 62 (38.8) 58 (37.4) 0.81 38 (38.0) 16 (30.2) 22 (41.5) 0.22 
Ethnicity – 
Caucasian 266 (84.4) 134 (83.8) 132 (85.2) 0.73 92 (86.8) 47 (88.7) 45 (84.9) 0.57 
Serum 
creatinine at 
enrollment 
(µmol/l) 
101 ± 66 100 ± 64 102 ± 69 0.73 154 ± 34 156 ± 37 152 ± 30 0.55 
Mean arterial 
pressure at 
baseline 
(mmHg) 
74.3 ± 8.4 74.6 ± 8.4 74.1 ± 8.4 0.86 72.2 ± 9.8 72.9 ± 10.4 71.5 ± 9.2 0.49 
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More severe 
shock (NE 
>15µg/min) 
131 (41.6) 72 (45.0) 59 (38.1) 0.26 66 (62.3) 33 (62.3) 33 (62.3) 1.0 
Cardiac Index 
at baseline 
(l/min/m2)** 
4.1 ± 1.5 4.0 ± 1.4 4.3 ± 1.5 0.43 3.6 ± 1.3 3.6 ± 1.4 3.5 ± 1.3 0.79 
Mechanically 
ventilated at 
inclusion 
301 (95.6) 157 (98.1) 144 (92.9) 0.03 96 (90.6) 45 (84.9) 51 (96.2) 0.05 
Comorbidities 
Ischemic 
heart disease 
Congestive 
heart failure 
Diabetes 
COPD 
 
45 (14.3) 
 
20 (6.3) 
 
55 (17.5) 
65 (20.6) 
 
25 (15.6) 
 
13 (8.1) 
 
32 (20.0) 
38 (23.8) 
 
20 (12.9) 
 
7 (4.5) 
 
23 (14.8) 
27 (17.4) 
 
0.49 
 
0.19 
 
0.22 
0.16 
 
15 (14.2) 
 
7 (6.6) 
 
20 (18.9) 
14 (13.2) 
 
8 (15.1) 
 
4 (7.5) 
 
11 (20.8) 
8 (15.1) 
 
7 (13.2) 
 
3 (5.7) 
 
9 (17.0) 
6 (11.3) 
 
0.78 
 
0.70 
 
0.62 
0.57 
28-day 
mortality 85 (27.0) 45 (28.1) 40 (25.8) 0.64 45 (42.9)* 29 (54.7) 16 (30.8) 0.01 
Adjusted 
OR## 
(99% CI) 
  1.07  (0.52-2.22) 0.81   
0.33  
(0.10-1.09) 0.02 
Need for RRT 
during 28-day 
study period 
36 (11.4) 20 (12.5) 16 (10.3) 0.54 29 (27.4) 20 (37.7) 9 (17.0) 0.02 
ICU length of 
stay (days) 18 (10-36) 18 (11-33.5) 17 (9-37) 0.73 14 (6–26) 14 (4-26) 14 (11-25) 0.60 
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 Injury Failure 
 Total NE AVP p-value# Total NE AVP p-value# 
Number  130 (16.7) 62 68  179 (23.0) 82 97  
Age 64.0 ± 14.8 64.8 ± 13.6 63.4 ± 16.0 0.63 61.9 ± 16.4 62.4 ± 16.0 61.5 ± 16.7 0.74 
Sex – male 75 (57.7) 32 (51.6) 43 (63.2) 0.25 99 (55.3) 43 (52.4) 56 (57.7) 0.58 
APACHE II 28.0 ± 7.7 27.1 ± 6.4 29.2 ± 7.8 0.06 31.3 ± 6.5 31.7 ± 6.5 31.1 ± 6.5 0.53 
Recent 
Surgery 49 (41.5) 20 (32.3) 29 (42.6) 0.22 62 (35.6) 25 (30.5) 37 (38.1) 0.28 
Ethnicity – 
Caucasian 113 (86.9) 51 (82.3) 62 (91.2) 0.28 147 (82.1) 66 (80.5) 81 (83.5) 0.60 
Serum 
creatinine at 
enrollment 
(µmol/l) 
205 ± 39 203 ± 36 207 ± 42 0.53 321 ± 123 333 ± 135 310 ± 112 0.21 
Mean arterial 
pressure at 
baseline 
(mmHg) 
72.0 ± 8.9 72.9 ± 8.2 71.2 ± 9.4 0.28 71.6 ± 11.4 72.2 ± 12.7 71.0 ± 10.2 0.46 
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More severe 
shock (NE 
>15µg/min) 
75 (57.7) 35 (56.5) 40 (58.8) 0.92 105 (58.7) 47 (57.3) 58 (59.8) 0.86 
Cardiac Index 
at baseline 
(l/min/m2)** 
3.5 ± 1.0 3.9 ± 1.1 3.3 ± 0.9 0.19 4.1 ± 1.3 4.3 ± 1.1 4.0 ± 1.3 0.42 
Mechanically 
ventilated at 
inclusion 
118 (90.8) 54 (87.1) 64 (94.1) 0.17 169 (94.4) 81 (98.8) 88 (90.7) 0.02 
Comorbidities 
Ischemic 
heart disease 
Congestive 
heart failure 
Diabetes 
COPD 
 
28 (21.5) 
 
12 (9.2) 
 
26 (20.0) 
11 (8.5) 
 
11 (17.7) 
 
5 (8.1) 
 
13 (21.0) 
6 (9.7) 
 
17 (25.0) 
 
7 (10.3) 
 
13 (19.1) 
5 (7.4) 
 
0.31 
 
0.66 
 
0.79 
0.63 
 
35 (19.6) 
 
13 (7.3) 
 
45 (25.1) 
31 (17.3) 
 
15 (18.3) 
 
5 (6.1) 
 
22 (26.8) 
18 (22.0) 
 
20 (20.6) 
 
8 (8.2) 
 
23 (23.7) 
13 (13.4) 
 
0.69 
 
0.58 
 
0.63 
0.13 
28-day 
mortality 51 (39.2) 22 (35.5) 29 (42.6) 0.47 82 (45.8) 39 (47.6) 43 (44.3) 0.67 
Adjusted 
OR## 
(99% CI) 
  1.44 (0.50-4.10) 0.37   
0.87 
(0.38-1.98) 0.67 
Need for RRT 
during 28-day 
study period 
47 (36.4) 23 (37.7) 24 (35.3) 0.78 135 (75.4) 60 (73.2) 75 (77.3) 0.52 
ICU length of 
stay (days) 12 (7-31) 13 (8-33) 12 (5-23.5) 0.15 15 (7-29.5) 15 (8-31) 16 (6-28) 0.55 
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End-stage 
p-value$ 
between RIFLE 
categories 
 Total NE AVP p-value#  
Number  49 (6.3) 25 24   
Age 62.3 ± 13.3 61.9 ± 12.2 62.6 ± 14.7 0.87 0.002 
Sex – male 29 (59.2) 16 (64.0) 13 (54.2) 0.68 0.25 
APACHE II 31.5 ± 6.1 30.1 ± 6.4 33.0 ± 5.4 0.09 <0.001 
Recent Surgery 14 (28.6) 9 (36.0) 5 (20.8) 0.24 0.37 
Ethnicity – 
Caucasian 38 (77.6) 22 (88.0) 16 (66.7) 0.07 0.48 
Serum 
creatinine at 
enrollment 
(µmol/l) 
472 ± 207 463 ± 181 480 ± 235 0.78 <0.001 
Mean arterial 
pressure at 
baseline 
(mmHg) 
70.1 ± 8.4 69.1 ± 10.2 71.2 ± 6.0 0.40 0.002 
  29 
More severe 
shock (NE 
>15µg/min) 
24 (49.0) 13 (52.0) 11 (45.8) 0.88 <0.001 
Cardiac Index 
at baseline 
(l/min/m2)** 
3.3 ± 0.4 3.4 ± 0.5 3.2 ± 0.3 0.48 0.10 
Mechanically 
ventilated at 
inclusion 
45 (91.8) 23 (92.0) 22 (91.7) 0.97 0.21 
Comorbidities 
Ischemic 
heart disease 
Congestive 
heart failure 
Diabetes 
COPD 
 
10 (20.4) 
 
6 (12.2) 
 
19 (38.8) 
6 (12.2) 
 
6 (24.0) 
 
3 (12.0) 
 
10 (40.0) 
2 (8.0) 
 
4 (16.7) 
 
3 (12.5) 
 
9 (37.5) 
4 (16.7) 
 
0.52 
 
0.96 
 
0.86 
0.14 
 
0.29 
 
0.60 
 
0.03 
0.01 
28-day 
mortality 27 (55.1) 15 (60.0) 12 (50.0) 0.48 <0.001 
Adjusted OR## 
(99% CI)   
0.67 
(0.13-3.47) 0.53  
Need for RRT 
during 28-day 
study period 
49 (100) 25 (100) 24 (100) - <0.001 
ICU length of 
stay (days) 15.5 (7-27.5) 14 (2-25.5) 20 (7.5-48.5) 0.25 0.006 
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Values are numbers (%) or mean ± SD or median (25-75th centiles). Patients’ “normal” creatinine was estimated in 394 / 779 (50.6%) of cases 
for RIFLE classification. *One patient in the “Risk” group was lost to follow up and therefore not included in the mortality analysis. **Cardiac 
index was measured in a subset of 153 patients at baseline. # p-values compares variable between NE and AVP group within RIFLE category. ## 
Adjusted OR refers to multivariate logistic regression model of 28-day mortality rates.  $Compares variable between RIFLE categories in all 
patients. RRT = renal replacement therapy, NE = norepinephrine, AVP = vasopressin. 
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Table 3. Multivariate logistic regression model for 28-day mortality in “Risk” 
category patients 
 Odds ratio 99% CI p-value 
Age  1.01 0.97 1.06 0.38 
Male sex 0.87 0.24 3.14 0.87 
APACHE II 1.04 0.94 1.16 0.31 
Surgical 
admission 0.61 0.18 2.08 0.30 
Dose of NE at 
baseline 1.03 1.00 1.06 0.02 
Vasopressin 
treatment 0.33 0.10 1.09 0.02 
NE = norepinephrine. For the continuous variables the odds ratio refers to each year 
of age, each point of APACHE II score, and each !g/min of norepinephrine. For 
dichotomous variables comparison references are male v female sex, surgical v 
medical admission, and vasopressin v norepinephrine treatment allocation.  
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Figure 1. Kaplan Meier survival curves for at “Risk” patients in the vasopressin-
treated group, solid black line, and the norepinephrine-treated group, dotted line (p = 
0.007). P value was calculated using the log rank statistic.  
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Figure 2. Mean serum creatinine (and 95%CI) over the first 20 days from start of 
study drug infusion in A – “Non-AKI” category, B – “Risk” category, C – “Injury” 
category, D – “Failure” category of RIFLE. Grey circles represent norepinephrine 
group, black squares represent vasopressin group. Serum creatinine values recorded 
whilst receiving renal replacement therapy have been excluded from the analysis. 
  35 
Data after day 20 has not been shown due to small numbers in each group. AVP = 
vasopressin, NE = norepinephrine 
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Figure 3.  Median (±IQR) norepinephrine infusion rates are shown (Panel A) for 
patients receiving open-label norepinephrine at baseline in vasopressin and in 
norepinephrine treatment groups of patients in VASST who were in the “Risk” 
category of acute kidney injury according to RIFLE.  Vasopressin-treated patients 
(black squares) had significantly reduced norepinephrine infusion rates compared to 
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the norepinephrine-treated patients (grey circles) (p < 0.001). Mean arterial pressure 
was similar between the two treatment groups (Panel B).  
 
